Rare Spinal Inflammation Listed By European Union As Side Effect Of Johnson & Johnson Vaccine

European Medicines Agency has listed a rare condition as a side effect of the Johnson & Johnson vaccine. The drug regulator of Europe has recommended adding transverse myelitis, a rare type of spinal condition as a side effect of the single-dose vaccine by Johnson & Johnson.

The early stages of the development of the vaccines by Johnson & Johnson and AstraZeneca, which were based on the same process, were halted. The development process was halted due to the reports of grave neurological conditions that came out in the public.

While giving updates on the safety of vaccines administered in the EU, the drug controller European Medicine Agency or the EMA, stated about another rare disease. Capillary Leak Syndrome or CLS is also being looked at with regards to the vaccine developed by Moderna.

Assessing reports, the EMA stated that they have recorded six cases that indicate CLS. However, they are yet to be sure about the relation between the vaccine by Moderna and the disease, as reported by Rappler.

Capillary Leak Syndrome, as the name suggests, is a disease where fluids come out from a leak in the blood vessels. The leak causes the fluid to come out and lead to internal hemorrhage, swelling as well as a severe drop in blood pressure.

This issue of CLS was under the scanner of EMA while they were studying vaccines from Johnson & Johnson and AstraZeneca. The EMA also has reported that they have not found any direct link between the vaccines in question and the diseases.

They iterated that there is not enough proof available to tag a linkage between the vaccines by Pfizer-BioNTech and Moderna based on mRNA, and multisystem inflammatory syndromes.

The drug regulatory body is looking at the approved COVID-19 vaccines as to whether it is causing the disorder or not. The multisystem inflammatory syndrome is a very serious issue that affects the brain, lungs, heart, kidneys and gastrointestinal system, NDTV pointed out. Although rare, the disorder can be fatal, which is why it has come to the attention of the regulatory body.

The drug manufacturers are yet to make any public statements regarding the EMA’s latest find.